A Randomized, Open-label, Controlled, Multi-center Two-year Study Comparing Efficacy and Safety of Telbivudine, 600 mg PO in Combination With Peginterferon Alpha-2a sq180 microg With Peginterferon Alpha-2a Monotherapy, and With Telbivudine Monotherapy in Treatment naive Patients With HBeAg-positive CHB.

Trial Profile

A Randomized, Open-label, Controlled, Multi-center Two-year Study Comparing Efficacy and Safety of Telbivudine, 600 mg PO in Combination With Peginterferon Alpha-2a sq180 microg With Peginterferon Alpha-2a Monotherapy, and With Telbivudine Monotherapy in Treatment naive Patients With HBeAg-positive CHB.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2015

At a glance

  • Drugs Telbivudine (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Sep 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 01 Sep 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 11 Jan 2008 Status changed from recruiting to suspended (for safety issues).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top